RxDoctor Payments Data

Matthew Hevey, MD

Infectious Disease · Colorado Springs, CONPI 1356769590

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (48.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Gilead accounts for 77.0% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2023 at $5,472 and has fallen 90.8% since, to $505 in 2025. Among infectious disease clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,679in general payments, 2019–2025

Across 131 payments — averaging $58.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$6K
  • Viiv Healthcare Company$881
  • Merck$271
  • AbbVie$185
  • Astellas Pharma US Inc$66
  • Shionogi Inc$48
  • plus $314 from 11 others

What the payments were for

  • Consulting fees$3,75049%
  • Travel & lodging$1,12515%
  • Food & beverage$2,77836%
  • Education$260%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,679 in reported general payments places this provider in the 90th percentile of 146 infectious disease providers in Colorado.

See all infectious disease providers in Colorado

Medicare billing

Part B allowed, 2024
$138,969
Medicare patients
301
Services billed
103,824

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala42$201,799
TriumeqAbacavir/Dolutegravir/Lamivudi12$51,001
JulucaDolutegravir/Rilpivirine14$49,428
OdefseyEmtricitab/Rilpiviri/Tenof Ala13$44,276
DovatoDolutegravir Sodium/Lamivudine13$36,374
Daptomycin13$13,498
Ampicillin Sodium12$5,217
CeftriaxoneCeftriaxone Sodium58$3,957
Cefadroxil42$3,832
ErtapenemErtapenem Sodium13$2,084
Cefazolin Sodium22$1,385
Ampicillin-SulbactamAmpicillin Sod/Sulbactam Sod19$1,222
Doxycycline Hyclate36$1,048
Vancomycin Hcl11$894
Cephalexin36$600

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$5,915$201,79942 claims
Viiv Healthcare CompanyTriumeq, Juluca, Dovato$881$136,80339 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 146 infectious disease providers in Colorado.

Other infectious disease in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →